与右乳腺癌相比,左乳腺癌的预后不同:系统性审查和元分析
Fausto Petrelli1, Antonio Ghidini2, Maria Antista3
1Oncology Unit, ASST Bergamo Ovest, Treviglio, BG, Italy.
Cancer epidemiology
|May 16, 2024
概括
与右侧瘤相比,左侧乳腺癌与存活率略低,心脏病死亡率增加10%有关. 这一元分析阐明了乳腺癌横向性的生存差异.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 生物统计学 生物统计学
背景情况:
- 乳腺癌的横向性 (左与右) 是关于其对患者结果的影响进行辩论的.
- 了解生存差异对于个性化治疗策略和风险评估至关重要.
研究的目的:
- 为了评估左侧乳腺癌和右侧乳腺癌之间整体存活率 (OS),心脏死亡率和癌症特异性存活率 (CSS) 的差异.
- 为乳腺癌横向性预后影响提供基于证据的见解.
主要方法:
- 进行了全面的元分析,搜索了PubMed,EMBASE和Cochrane图书馆的数据库,截至2023年12月1日.
- 包括50个出版物,涵盖7,527,156名患者.
- 主要终点是OS;次要终点包括心脏病死亡率和CSS.
主要成果:
- 左侧乳腺癌与小幅下降的OS相关 (HR=1.03,P<.01).
- 对左侧BC (HR=1.1,P<.01) 观察到心脏死亡率显著增加10%.
- 癌症特异性存活率 (CSS) 在左侧和右侧乳腺癌之间没有显著差异 (HR=1.01,P=.32).
结论:
- 与右侧BC相比,左侧乳腺癌的死亡风险略有增加,心脏相关死亡人数显著增加.
- 虽然CSS是相似的,但心脏死亡率的增加凸显了与左侧瘤相关的潜在特定脆弱性.
相关概念视频
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Comparing the Survival Analysis of Two or More Groups
177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
Kaplan-Meier Approach
133
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
133


